Zelira Therapeutics (ASX:ZLD) Secures $1.15M R&D Tax Refund
Funding Received
Zelira Therapeutics Ltd (ASX:ZLD) has received a $1,153,000 cash refund under the Australian Federal Government’s R&D Tax Incentive Scheme.
Use of Funds
The funds will be allocated to working capital for advancing Zelira’s clinical development programs and business operations, including pipeline product initiatives.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.